1. Scrip
  2. >>Business
  3. >>Financing

Seventure Reaffirms Microbiome Confidence With New €200m Fund

 
• By Mike Ward

With its first microbiome fund completing its investment period, French venture capitalist Seventure Partners has raised more than €100m of a €200m target for its second microbiome-focused fund.

3d render illustration of human digestive system - front view
Exponential increase in microbiome potential

Seventure Partners is doubling down in the microbiome space with a new €200m fund Health for Life Capital II (HFL II). With 90% of limited partners from the first fund returning to back the new fund, the French VC has been able to announce a first closing north of €100m. Moreover, it has already started putting the new money to work participating in the $25m series B round completed by Axial Biotech Inc. and the Galecto Biotech AB €79m series C round.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.